Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | BMC Cancer

Fig. 4

From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Fig. 4

FRAX597 inhibits proliferation, migration/invasion, and survival. The effect of the selective group 1-PAK inhibitor FRAX597 on cell proliferation (a), cell migration/invasion (b) and cell survival (c) of the indicated human pancreatic cancer cell lines was measured using the thymidine-incorporation method, the Transwell Boyden chamber assay, and the thymidine-withdrawal method, respectively. The values for the untreated cells were taken as 100 %. The data represent mean ± SEM, summarised from three independent experiments. Significance is not shown for clarity

Back to article page